Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

Executive Summary

During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.


Related Content

IPO Update: With No New Offerings, Kadmon Steals The Spotlight
IPO Update: Haircuts Needed To Price Biotech Offerings
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Biotech VC Funding Rises As Fewer Companies Get More Dollars
Mersana/Takeda Deal Adds To ADC Pipeline
INFOGRAPHIC: A US biotech IPO surge? Data are mixed
CRISPR Therapeutics raises $64m 'validating' uncertain patent position
Mersana raises $35m, names former Millennium president CEO
Elan veterans grab $34m for neurodegenerative diseases
Merck Serono enters antibody drug conjugate fray


Related Companies